Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6638MR)

This product GTTS-WQ6638MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6638MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10347MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ1738MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ7819MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ10562MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ6931MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ3207MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ5773MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ8230MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HLX-06
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW